Swiss drugmaker Novartis will buy New Jersey biotech The Medicines Company to expand its portfolio of cardiovascular drugs
Swiss pharmaceutical company Novartis has reached a deal to buy cholesterol drugmaker The Medicines Company for $9.7 billion.
Novartis will pay $85 per share for the New Jersey biotech company, a sharp increase over The Medicine Co.’s Friday closing price of $68.55 per share. The deal is worth $9.7 billion, including outstanding stock options and convertible debt.
The Medicines Co. is in late-stage studies of a drug, inclisiran, meant to lower cholesterol.
Novartis has a pattern of acquiring other companies in recent years to expand its portfolio of drugs.
The deal is expected to close early next year.
Get more stuff like this
Subscribe to our mailing list and get interesting stuff and updates to your email inbox.